Tarsier Pharma to IPO 5.56M Shares at $8-10; 10-for-1 Forward Split

Tarsier Pharma Ltd. filed an amendment to its F-1 registration statement for an initial public offering of 5,555,555 ordinary shares, with an anticipated price range of $8.00 to $10.00 per share. The company plans to list its shares on the NYSE under the symbol "TARX". Prior to the offering, a 10-for-1 forward stock split will be effected. Tarsier Pharma is an emerging growth company and a foreign private issuer, developing novel therapies for blinding eye diseases, including lead product candidate TRS01 for uveitis and uveitic glaucoma.